Overview

ESBA1008 Microvolume Study

Status:
Completed

Trial end date:
2015-01-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to demonstrate a treatment effect of ESBA1008 applied as a microvolume injection or infusion on retinal function and morphology in subjects with exudative age-related macular degeneration (AMD).

Phase:

Phase 2

Details

Lead Sponsor:

Alcon Research

Treatments:

Ranibizumab